These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1751019)

  • 1. Effect of ursodeoxycholic acid on experimental hepatic porphyria induced by griseofulvin.
    Choi SW; Han JH; Lim KT; Cho HM; Chung KW; Sun HS; Park DH; Kim BS; Seo EJ
    J Korean Med Sci; 1991 Jun; 6(2):146-56. PubMed ID: 1751019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholic acid amelioration of light and electron microscopic hepatic lesions in experimental protoporphyria.
    Lefkowitch JH; Feng-Chen KC; Sklar JA; Poh-Fitzpatrick MB
    Hepatology; 1983; 3(3):399-406. PubMed ID: 6840685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The influence of ursodesoxycholic acid (URSO) on griseofulvin (GF)-induced protoporphyria].
    Irifune H; Tsukazaki N; Watanabe M; Nonaka S
    Nihon Hifuka Gakkai Zasshi; 1991 Jul; 101(8):813-7. PubMed ID: 1942584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrastructural changes of intrahepatic bile ductules in griseofulvin fed mice.
    Shapiro SH; Wessely Z
    Ann Clin Lab Sci; 1984; 14(1):69-77. PubMed ID: 6696389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental murine protoporphyria induced by griseofulvin (GF): the relationship between hepatic porphyrin levels and liver function test values in mice treated with GF.
    Tanaka K; Ohgami T; Nonaka S
    J Dermatol; 1993 Sep; 20(9):545-53. PubMed ID: 8227709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of bile acid structure in amelioration of griseofulvin-induced murine protoporphyric hepatopathy.
    Berenson MM; Welch V; Garcia-Marin JJ
    J Lab Clin Med; 1991 Jul; 118(1):89-98. PubMed ID: 2066649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Light and electron microscopy of hepatocellular changes in griseofulvin fed mice. Particular reference to Mallory bodies.
    Wessely Z; Shapiro SH; Klavins JV
    Ann Clin Lab Sci; 1979; 9(1):24-36. PubMed ID: 420510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxic effects of griseofulvin: disease models, mechanisms, and risk assessment.
    Knasmüller S; Parzefall W; Helma C; Kassie F; Ecker S; Schulte-Hermann R
    Crit Rev Toxicol; 1997 Sep; 27(5):495-537. PubMed ID: 9347226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental induction of hepatocellular hyalin (Mallory bodies) in mice by griseofulvin treatment. 1. Light microscopic observation.
    Denk H; Eckerstorfer R; Gschnait F; Konrad K; Wolff K
    Lab Invest; 1976 Oct; 35(4):377-82. PubMed ID: 62098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excretory function in cultured hepatocytes from griseofulvin-treated mice.
    Kawahara H; Marceau N; French SW
    Lab Invest; 1989 Dec; 61(6):609-22. PubMed ID: 2481150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protoporphyrin hepatopathy. Effects of cholic acid ingestion in murine griseofulvin-induced protoporphyria.
    Poh-Fitzpatrick MB; Sklar JA; Goldsman C; Lefkowitch JH
    J Clin Invest; 1983 Oct; 72(4):1449-58. PubMed ID: 6630515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ursodeoxycholic acid on intrahepatic cholestasis in rats.
    Li L; Xu X; Lu F; Zhao N
    Chin Med J (Engl); 2003 Jul; 116(7):1099-103. PubMed ID: 12890392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.
    Matsuzaki Y; Tanaka N; Osuga T; Aikawa T; Shoda J; Doi M; Nakano M
    Am J Gastroenterol; 1990 Jan; 85(1):15-23. PubMed ID: 1967512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Griseofulvin-induced cholestasis in Swiss albino mice.
    Yokoo H; Craig RM; Harwood TR; Cochrane C
    Gastroenterology; 1979 Nov; 77(5):1082-7. PubMed ID: 488635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse model for protoporphyria. I. The liver and hepatic protoporphyrin crystals.
    Gschnait F; Konrad K; Hönigsmann H; Denk H; Wolff K
    J Invest Dermatol; 1975 Sep; 65(3):290-9. PubMed ID: 1159316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manifestation of psychiatric behaviors in a mouse model of griseofulvin-induced hepatic porphyria.
    Satoh Y; Iwadate R; Watanabe Y; Kawai H; Kudo N; Kawashima Y; Mitsumoto A
    J Toxicol Sci; 2008 Dec; 33(5):599-608. PubMed ID: 19043281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
    Laurin J; Lindor KD; Crippin JS; Gossard A; Gores GJ; Ludwig J; Rakela J; McGill DB
    Hepatology; 1996 Jun; 23(6):1464-7. PubMed ID: 8675165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Morphological changes in liver tissue in experimental porphyria].
    Chlumská A; Dobiás J; Janousek V
    Cesk Patol; 1978 May; 14(2):57-63. PubMed ID: 699108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ursodeoxycholic acid limits liver histologic alterations and portal hypertension induced by bile duct ligation in the rat.
    Poo JL; Feldmann G; Erlinger S; Braillon A; Gaudin C; Dumont M; Lebrec D
    Gastroenterology; 1992 May; 102(5):1752-9. PubMed ID: 1568585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study.
    Günsar C; Melek M; Karaca I; Sencan A; Mir E; Ortaç R; Canan O
    Hepatogastroenterology; 2002; 49(44):497-500. PubMed ID: 11995481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.